

Herpes Zoster (Shingles) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/HB6CC291F7AEN.html>

Date: March 2020

Pages: 69

Price: US\$ 2,000.00 (Single User License)

ID: HB6CC291F7AEN

Abstracts

Herpes Zoster (Shingles) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2020, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2,

8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Herpes Zoster (Shingles) - Overview
- Herpes Zoster (Shingles) - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Herpes Zoster (Shingles) - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
 - Akshaya Bio Inc
 - Beijing Minhai Biotechnology Co Ltd
 - CanSino Biologics Inc
 - Changchun Bcht Biotechnology Co Ltd
 - CPL Biologicals Pvt Ltd
 - DongKoo Bio & Pharma Co Ltd
 - GC Pharma
 - GeneOne Life Science Inc
 - GlaxoSmithKline Plc
 - NAL Pharmaceuticals Ltd
 - NanoViricides Inc
 - Shulov Innovative Science Ltd
 - Vaccitech Ltd
 - Vapogenix Inc
 - XBiotech Inc
- Herpes Zoster (Shingles) - Drug Profiles
 - B-1006 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - CRV-101 - Drug Profile
 - Product Description

Mechanism Of Action
R&D Progress
CSB-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varicella zoster vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Herpes Zoster (Shingles) - Dormant Projects

Herpes Zoster (Shingles) - Discontinued Products

Herpes Zoster (Shingles) - Product Development Milestones

Featured News & Press Releases

Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered

Jan 30, 2020: NanoViricides confirms it has been working on a treatment for the novel Wuhan Coronavirus

Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101

Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate

Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT

Dec 03, 2019: NanoViricides founder Dr. Diwan provides \$2,000,000 loan commitment to the company

Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND

Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials

Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND

Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101

Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses

Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101

Aug 26, 2019: NanoViricides advancing rapidly towards first IND

Aug 05, 2019: NanoViricides reports its first drug candidate is on track with GLP safety/toxicology studies toward human clinical trials

Jul 10, 2019: Shingles vaccine safely prevents outbreaks among stem cell transplant patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Herpes Zoster (Shingles), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, H1 2020

Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H1 2020

Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by GC Pharma, H1 2020

Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2020

Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2020

Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2020

Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H1 2020

Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H1 2020

Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2020

Herpes Zoster (Shingles) - Dormant Projects, H1 2020

Herpes Zoster (Shingles) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Herpes Zoster (Shingles), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Akshaya Bio Inc

Beijing Minhai Biotechnology Co Ltd

CanSino Biologics Inc

Changchun Bcht Biotechnology Co Ltd

CPL Biologicals Pvt Ltd

DongKoo Bio & Pharma Co Ltd

GC Pharma

GeneOne Life Science Inc

GlaxoSmithKline Plc

NAL Pharmaceuticals Ltd

NanoViricides Inc

Shulov Innovative Science Ltd

Vaccitech Ltd

Vapogenix Inc

XBiotech Inc

I would like to order

Product name: Herpes Zoster (Shingles) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/HB6CC291F7AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HB6CC291F7AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970